Published • loading... • Updated
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
Divarasib showed statistically significant gains in progression-free and overall survival, and Roche said the safety profile remained consistent with earlier data.
- On Thursday, July 2, 2026, Roche announced positive Phase III Krascendo 1 results showing divarasib significantly improved progression-free and overall survival compared to approved KRAS G12C inhibitors sotorasib and adagrasib in advanced lung cancer.
- The KRAS G12C mutation locks proteins in an active state, driving continuous tumor growth. First-generation inhibitors like sotorasib and adagrasib reached the market but faced drug resistance challenges, creating demand for more potent next-generation options.
- In the 338-patient study, divarasib met its primary and secondary endpoints with statistically significant survival improvements. Roche reported no new safety signals, with treatment-related side effects "manageable and reversible" throughout the trial.
- Roche plans to submit data to health authorities and present findings at an upcoming medical meeting. Chief Medical Officer Levi Garraway stated the results "should establish divarasib as a new standard of care" for previously treated patients.
- Beyond the current trial, Roche is evaluating divarasib in Krascendo 2 and Krascendo 3 studies for first-line and adjuvant settings. The company competes with MSD and Eli Lilly, who are also advancing next-generation KRAS inhibitors in phase 3.
Insights by Ground AI
11 Articles
11 Articles
The Norfolk Daily NewsReposted by 
Business Wire
Business WireGenentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C
Globe Newswire+2 Reposted by 2 other sources
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib...
Coverage Details
Total News Sources11
Leaning Left1Leaning Right1Center5Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
14%
C 72%
14%
Factuality
To view factuality data please Upgrade to Premium
